Claim Amendments

1. (Previously presented). A compound of Formula (I)



(I)

wherein

R^1 is an optionally substituted aryl or an optionally substituted heteroaryl;

R^2 is an optionally substituted aryl;

R^3 is hydrogen, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, or $(C_1\text{-}C_4)$alkoxy;

R^4 is

(i) a group having Formula (IA)



IA

where

R^{4b} and $R^{4b'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, $(C_1\text{-}C_4)$alkyl)$_2$N-C(O)-, $(C_1\text{-}C_6)$alkylamino-, $((C_1\text{-}C_4)$alkyl)$_2$amino-, $(C_3\text{-}C_6)$cycloalkylamino-, acylamino-, aryl$(C_1\text{-}C_4)$alkylamino-, heteroaryl$(C_1\text{-}C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4b} or $R^{4b'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond, $-CH_2CH_2-$ or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, $((C_1\text{-}C_4)$alkyl)$_2$N-C(O)-, $(C_1\text{-}C_6)$alkylamino-,

di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4c} or $R^{4c'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge or an ethylene bridge;

Y is oxygen, sulfur, -C(O)-, or -C(R^{4d})($R^{4d'}$)-, where R^{4d} and $R^{4d'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, ((C_1-C_4)alkyl)$_2$N-C(O)-, (C_1-C_6)alkylamino-, di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, or

Y is –N$R^{4d''}$-, where $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_3)alkylsulfonyl-, (C_1-C_3)alkylaminosulfonyl-, di(C_1-C_3)alkylaminosulfonyl-, acyl, (C_1-C_6)alkyl-O-C(O)-, aryl, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

Z is a bond, –CH_2CH_2-, or -C(R^{4e})($R^{4e'}$)-, where R^{4e} and $R^{4e'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, ((C_1-C_4)alkyl)$_2$N-C(O)-, (C_1-C_6)alkylamino-, di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4e} or $R^{4e'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge; and

R^{4f} and $R^{4f'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, acyloxy, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $((C_1$-$C_4)$alkyl$)_2$N-C(O)-, $(C_1$-$C_6)$alkylamino-, di$(C_1$-$C_4)$alkylamino-, $(C_3$-$C_6)$cycloalkylamino-, acylamino-, aryl$(C_1$-$C_4)$alkylamino-, heteroaryl$(C_1$-$C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4f} or $R^{4f'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

2. (Previously presented). The compound of Claim 1 wherein R^4 is a group having Formula (IA)



IA

where,

R^{4b} and $R^{4b'}$ are each independently hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl$)_2$N-C(O)-, aryl, heteroaryl, a partially or fully saturated 3-6 membered heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4b} or $R^{4b'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond, $-CH_2CH_2$- or $-C(R^{4c})(R^{4c'})$-, where R^{4c} is hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, acyloxy, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl$)_2$N-C(O)-, $(C_1$-$C_6)$alkylamino-, $((C_1$-$C_4)$alkyl$)_2$amino-, $(C_3$-$C_6)$cycloalkylamino-, acylamino-, aryl$(C_1$-$C_4)$alkylamino-, heteroaryl$(C_1$-$C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4c} taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge, and

$R^{4c'}$ is hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl)$_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or $R^{4c'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

Y is oxygen, sulfur, -C(O)-, or -C(R^{4d})($R^{4d'}$)-, where R^{4d} is hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, acyloxy, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl)$_2$N-C(O)-, $(C_1$-$C_6)$alkylamino-, $((C_1$-$C_4)$alkyl)$_2$amino-, $(C_3$-$C_6)$cycloalkylamino-, acylamino-, aryl$(C_1$-$C_4)$alkylamino-, heteroaryl$(C_1$-$C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents, and

$R^{4d'}$ is hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl)$_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, or

Y is –N$R^{4d''}$-, where $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_1$-$C_3)$alkylsulfonyl-, $(C_1$-$C_3)$alkylaminosulfonyl-, di$(C_1$-$C_3)$alkylaminosulfonyl-, acyl, $(C_1$-$C_6)$alkyl-O-C(O)-, aryl, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

Z is a bond, –CH_2CH_2-, or -C(R^{4e})($R^{4e'}$)-, where R^{4e} is hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, acyloxy, acyl, $(C_1$-$C_3)$alkyl-O-C(O)-, $(C_1$-$C_4)$alkyl-NH-C(O)-, $(C_1$-$C_4)$alkyl)$_2$N-C(O)-, $(C_1$-$C_6)$alkylamino-, $((C_1$-$C_4)$alkyl)$_2$amino-, $(C_3$-$C_6)$cycloalkylamino-, acylamino-, aryl$(C_1$-

C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4e} taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge, and

$R^{4e'}$ is hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, (C_1-C_4)alkyl)$_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or $R^{4e'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge; and

R^{4f} and $R^{4f'}$ are each independently hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, (C_1-C_4)alkyl)$_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4f} or $R^{4f'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

3. (Previously presented). The compound of Claim of 2 wherein

R^1 and R^2 are each independently a substituted phenyl;

R^{4b} is hydrogen, an optionally substituted (C_1-C_3)alkyl, or taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

$R^{4b'}$ is hydrogen, an optionally substituted (C_1-C_3)alkyl, or taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

R^{4f} is hydrogen, an optionally substituted (C_1-C_3)alkyl, or taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge; and

$R^{4f'}$ is hydrogen, an optionally substituted (C_1-C_3)alkyl, or taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

4. (Previously presented). The compound of Claim 3 wherein

X is -C(R^{4c})($R^{4c'}$)-, where R^{4c} and $R^{4c'}$ are each independently hydrogen, $H_2NC(O)$-, or a chemical moiety selected from (C_1-C_6)alkyl, (C_1-C_4)alkyl-NH-C(O)-, or ((C_1-C_4)alkyl)$_2$N-C(O)-, where said moiety is optionally substituted with one or more substituents,

or either R^{4c} or $R^{4c'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge or an ethylene bridge;

Y is –N$R^{4d''}$-, where $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_3)alkylsulfonyl, (C_1-C_3)alkylaminosulfonyl, di(C_1-C_3)alkylaminosulfonyl, acyl, (C_1-C_6)alkyl-O-C(O)-, aryl, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

Z is -C(R^{4e})($R^{4e'}$)-, where R^{4e} and $R^{4e'}$ are each independently hydrogen, $H_2NC(O)$-, or a chemical moiety selected from C_1-C_6)alkyl, (C_1-C_4)alkyl-NH-C(O)-, or ((C_1-C_4)alkyl)$_2$N-C(O)-, where said moiety is optionally substituted with one or more substituents,

or either R^{4e} or $R^{4e'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

5. (Previously presented). The compound of Claim 4 wherein $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of (C_1-C_3)alkyl, (C_1-C_3)alkylsulfonyl, (C_1-C_3)alkylaminosulfonyl, di(C_1-C_3)alkylaminosulfonyl, acyl, (C_1-C_6)alkyl-O-C(O)-, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof.

6. (Previously presented). The compound of Claim 5 wherein $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of (C_1-C_3)alkyl, (C_1-C_3)alkylsulfonyl, (C_1-C_3)alkylaminosulfonyl, di(C_1-C_3)alkylaminosulfonyl, acyl, and (C_1-C_6)alkyl-O-C(O)-, where said moiety is optionally substituted with 1-3 fluorines,

or $R^{4d''}$ is a heteroaryl, where said heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C_1-C_3)alkoxy, (C_1-C_3)alkyl, and fluoro-substituted (C_1-C_3)alkyl;

a pharmaceutically acceptable salt thereof.

7. (Previously presented). The compound of Claim 4, 5 or 6 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 3 substituents independently selected from

the group consisting of halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

8. (Previously presented). The compound of Claim 7 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, fluoro-substituted (C_1-C_4)alkyl), and cyano;

a pharmaceutically acceptable salt thereof.

9. (Previously presented). The compound of Claim 8 wherein R^1 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^2 is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof.

10. (Previously presented). The compound of Claim 9 selected from the group consisting of

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-methylpiperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-[(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-[4-(propane-2-sulfonyl)-piperazin-1-yl]-pyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-ethanesulfonyl)-piperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-piperazin-1-yl-pyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-methanesulfonyl)-piperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine;

(1S,4S)-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpyrazolo[1,5-a][1,3,5]triazine;

1-{(1S,4S)-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}-ethanone;

1-{(1S,4S)-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}-2-methylpropan-1-one;

1-{(1S,4S)-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}-phenylmethanone;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-[(1S,4S)-5-ethanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpyrazolo[1,5-a][1,3,5]triazine;

7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-[(1S,4S)-5-(propane-2-sulfonyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-pyrazolo[1,5-a][1,3,5]triazine; and

(1S,4S)-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]- 2,5-diazabicyclo[2.2.1]heptane-2-sulfonic acid dimethylamide;

a pharmaceutically acceptable salt thereof.

11. (Previously presented). The compound of Claim 3 wherein Y is $-C(R^{4d})(R^{4d'})-$, where R^{4d} is hydrogen, cyano, hydroxy, amino, $H_2NC(O)-$, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, (C_1-C_4)alkyl$)_2$N-C(O)-, (C_1-C_6)alkylamino-, $((C_1-C_4)$alkyl$)_2$amino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

$R^{4d'}$ is hydrogen, $H_2NC(O)-$, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, (C_1-C_4)alkyl$)_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof.

12. (Previously presented). The compound of Claim 11 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen;

R^{4d} is amino, $(C_1\text{-}C_6)$alkylamino, di$(C_1\text{-}C_4)$alkylamino, $(C_3\text{-}C_6)$cycloalkylamino, acylamino, aryl$(C_1\text{-}C_4)$alkylamino-, heteroaryl$(C_1\text{-}C_4)$alkylamino-; and

$R^{4d'}$ is $(C_1\text{-}C_6)$alkyl, $H_2NC(O)$-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, or $((C_1\text{-}C_4)\text{alkyl})_2$N-C(O)-, or aryl;

a pharmaceutically acceptable salt thereof.

13. (Previously presented). The compound of Claim 12 wherein

X is a bond or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each hydrogen; and

Z is a bond or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each hydrogen;

a pharmaceutically acceptable salt thereof.

14. (Previously presented). The compound of Claim 13 wherein R^{4d} is amino, $(C_1\text{-}C_6)$alkylamino, di$(C_1\text{-}C_4)$alkylamino, $(C_3\text{-}C_6)$cycloalkylamino; and

$R^{4d'}$ is $H_2NC(O)$-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, or $((C_1\text{-}C_4)\text{alkyl})_2$N-C(O)-;

a pharmaceutically acceptable salt thereof.

15. (Previously presented). The compound of Claim 11, 12, 13 or 14 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

16. (Previously presented). The compound of Claim 15 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, fluoro-substituted $(C_1\text{-}C_4)$alkyl), and cyano;

a pharmaceutically acceptable salt thereof.

17. (Previously presented). The compound of Claim 16 selected from the group consisting of

1-[7-(2-chlorophenyl)-8-(2,4-dichlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7,8-bis-(2-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-cyanophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-methylphenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-ethylphenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; and

1-[7-(2-chlorophenyl)-8-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

a pharmaceutically acceptable salt thereof.

18. (Previously presented). The compound of Claim 16 wherein R^1 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^2 is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof.

19. (Previously presented). The compound of Claim 18 selected from the group consisting of

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-methylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide;

3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-methylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-dimethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; and

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-methylaminoazetidine-3-carboxylic acid amide;

a pharmaceutically acceptable salt thereof.

20. (Previously presented). The compound of Claim 19 selected from the group consisting of

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide;

3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-methylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; and

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

a pharmaceutically acceptable salt thereof.

21. (Previously presented). The compound of Claim 11 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen;

R^{4d} is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_6)alkylamino-, and di(C_1-C_4)alkylamino-, where said moiety is optionally substituted with one or more substituents; and

$R^{4d'}$ is hydrogen, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, aryl and heteroaryl, where said moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof.

22. (Previously presented). The compound of Claim 21 wherein

X is a bond or -C(R^{4c})($R^{4c'}$)-, where R^{4c} and $R^{4c'}$ are each independently hydrogen or an optionally substituted (C_1-C_6)alkyl, or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond, a methylene bridge or an ethylene bridge; and

Z is a bond or -C(R^{4e})($R^{4e'}$)-, where R^{4e} and $R^{4e'}$ are each independently hydrogen or an optionally substituted (C_1-C_6)alkyl, or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

23. (Previously presented). The compound of Claim 22 wherein

R^{4c} and $R^{4c'}$ are each hydrogen or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond;

R^{4d} is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of (C_1-C_6)alkoxy, acyl, (C_1-C_6)alkylamino-, and di(C_1-C_4)alkylamino-;

$R^{4d'}$ is hydrogen, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl and aryl, where said moiety is optionally substituted with one or more substituents; and

R^{4e} and $R^{4e'}$ are hydrogen or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond;

a pharmaceutically acceptable salt thereof.

24. (Previously presented). The compound of Claim 21, 22, or 23 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 3 substituents independently selected

from the group consisting of halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

25. (Previously presented). The compound of Claim 24 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, fluoro-substituted (C_1-C_4)alkyl), and cyano;

a pharmaceutically acceptable salt thereof.

26. (Previously presented). The compound of Claim 25 wherein R^1 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^2 is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof.

27. (Previously presented). The compound of Claim 26 selected from the group consisting of

1-{1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-phenylpiperidin-4-yl}-ethanone;

3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-azabicyclo[3.1.0]hex-6-ylamine;

1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-(4-fluorophenyl)-piperidin-4-ol; and

4-benzyl-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-piperidin-4-ol;

a pharmaceutically acceptable salt thereof.

28. (Previously presented). The compound of Claim 11 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen; and

R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring or said lactam ring optionally contains an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof.

29. (Previously presented). The compound of Claim 28 wherein

X is a bond, $-CH_2CH_2-$ or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each independently hydrogen or an optionally substituted (C_1-C_6)alkyl, or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond, a methylene bridge or an ethylene bridge; and

Z is a bond, $-CH_2CH_2-$ or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each independently hydrogen or an optionally substituted (C_1-C_6)alkyl, or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

30. (Previously presented). The compound of Claim 28 wherein R^{4d} and $R^{4d'}$ taken together form a 5-6 membered lactam ring, where said lactam ring is optionally substituted with one or more substituents and optionally contains an additional heteroatom selected from nitrogen or oxygen;

a pharmaceutically acceptable salt thereof.

31. (Previously presented). The compound of Claim 30 wherein

X is a bond or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each hydrogen; and

Z is a bond or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each hydrogen;

a pharmaceutically acceptable salt thereof.

32. (Previously presented). The compound of Claim 28, 29, 30 or 31 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

33. (Previously presented). The compound of Claim 32 wherein R^1 and R^2 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, fluoro-substituted (C_1-C_4)alkyl), and cyano;

a pharmaceutically acceptable salt thereof.

34. (Previously presented). The compound of Claim 33 wherein R^1 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^2 is 4-chlorophenyl or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof.

35. (Previously presented). The compound of Claim 34 selected from the group consisting of

2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-5-methyl-2,5,7-triazaspiro[3.4]octan-8-one;

2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5,7-triazaspiro[3.4]octan-8-one;

8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; and

2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-6,6-dimethyl-2,5,7-triazaspiro[3.4]octan-8-one;

a pharmaceutically acceptable salt thereof.

36. (Previously presented). The compound of Claim 35 which is

8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one;

a pharmaceutically acceptable salt thereof.

37-55 (cancelled).

56. (Previously presented). A compound of Formula (II)



(II)

wherein

R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, or cyano;

n and m are each independently 0, 1 or 2;

R^3 is hydrogen, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, or $(C_1\text{-}C_4)$alkoxy; and

R^4 is

(i) a group having Formula (IA)



IA

where R^{4a} is hydrogen or $(C_1\text{-}C_3)$alkyl;

R^{4b} and $R^{4b'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, $(C_1\text{-}C_4)$alkyl)$_2$N-C(O)-, $(C_1\text{-}C_6)$alkylamino-, $((C_1\text{-}C_4)$alkyl)$_2$amino-, $(C_3\text{-}C_6)$cycloalkylamino-, acylamino-, aryl$(C_1\text{-}C_4)$alkylamino-, heteroaryl$(C_1\text{-}C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4b} or $R^{4b'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

X is a bond, $-CH_2CH_2$- or $-C(R^{4c})(R^{4c'})$-, where R^{4c} and $R^{4c'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, $((C_1\text{-}C_4)$alkyl)$_2$N-C(O)-, $(C_1\text{-}C_6)$alkylamino-, di$(C_1\text{-}C_4)$alkylamino-, $(C_3\text{-}C_6)$cycloalkylamino-, acylamino-, aryl$(C_1\text{-}C_4)$alkylamino-, heteroaryl$(C_1\text{-}C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4c} or $R^{4c'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge or an ethylene bridge;

Y is oxygen, sulfur, -C(O)-, or -C(R^{4d})($R^{4d'}$)-, where R^{4d} and $R^{4d'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, ((C_1-C_4)alkyl)$_2$N-C(O)-, (C_1-C_6)alkylamino-, di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated carbocyclic ring, a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where the carbocyclic ring, the heterocyclic ring, the lactone ring and the lactam ring are optionally substituted with one or more substituents and the lactone ring and the lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, or

Y is –N$R^{4d''}$-, where $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_1-C_3)alkylsulfonyl-, (C_1-C_3)alkylaminosulfonyl-, di(C_1-C_3)alkylaminosulfonyl-, acyl, (C_1-C_6)alkyl-O-C(O)-, aryl, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

Z is a bond, –CH_2CH_2-, or -C(R^{4e})($R^{4e'}$)-, where R^{4e} and $R^{4e'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, ((C_1-C_4)alkyl)$_2$N-C(O)-, (C_1-C_6)alkylamino-, di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4e} or $R^{4e'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge; and

R^{4f} and $R^{4f'}$ are each independently hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, acyloxy, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, ((C_1-C_4)alkyl)$_2$N-C(O)-, (C_1-C_6)alkylamino-, di(C_1-C_4)alkylamino-, (C_3-C_6)cycloalkylamino-, acylamino-, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-, aryl, heteroaryl, a 3-6 membered partially

or fully saturated heterocycle, and a 3-6 membered partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or either R^{4f} or $R^{4f'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

57. (Cancelled).

58. (Previously presented). The compound of Claim 56 wherein

R^{4b} is hydrogen, an optionally substituted $(C_1\text{-}C_3)$alkyl, or taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

$R^{4b'}$ is hydrogen, an optionally substituted $(C_1\text{-}C_3)$alkyl, or taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge, or an ethylene bridge;

R^{4f} is hydrogen, an optionally substituted $(C_1\text{-}C_3)$alkyl, or taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge; and

$R^{4f'}$ is hydrogen, an optionally substituted $(C_1\text{-}C_3)$alkyl, or taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge, or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

59. (Previously presented). The compound of Claim 58 wherein

X is $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each independently hydrogen, $H_2NC(O)-$, or a chemical moiety selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, or $((C_1\text{-}C_4)\text{alkyl})_2N\text{-}C(O)-$, where said moiety is optionally substituted with one or more substituents,

or either R^{4c} or $R^{4c'}$ taken together with R^{4e}, $R^{4e'}$, R^{4f}, or $R^{4f'}$ forms a bond, a methylene bridge or an ethylene bridge;

Y is $-NR^{4d''}-$, $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_1\text{-}C_3)$alkylsulfonyl, $(C_1\text{-}C_3)$alkylaminosulfonyl, di$(C_1\text{-}C_3)$alkylaminosulfonyl, acyl, $(C_1\text{-}C_6)$alkyl-O-C(O)-, aryl, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

Z is $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each independently hydrogen, $H_2NC(O)-$, or a chemical moiety selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, or $((C_1\text{-}C_4)\text{alkyl})_2N\text{-}C(O)-$, where said moiety is optionally substituted with one or more substituents,

or either R^{4e} or $R^{4e'}$ taken together with R^{4b}, $R^{4b'}$, R^{4c}, or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

60. (Previously presented). The compound of Claim 59 wherein $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of $(C_1\text{-}C_3)$alkylsulfonyl, $(C_1\text{-}C_3)$alkylaminosulfonyl, di$(C_1\text{-}C_3)$alkylaminosulfonyl, acyl, $(C_1\text{-}C_6)$alkyl-O-C(O)-, and heteroaryl, where said moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof.

61. (Previously presented). The compound of Claim 60 wherein $R^{4d''}$ is a hydrogen or a chemical moiety selected from the group consisting of $(C_1\text{-}C_3)$alkylsulfonyl, $(C_1\text{-}C_3)$alkylaminosulfonyl, di$(C_1\text{-}C_3)$alkylaminosulfonyl, acyl, and $(C_1\text{-}C_6)$alkyl-O-C(O)-, where said moiety is optionally substituted with 1-3 fluorines,

or $R^{4d''}$ is a heteroaryl, where said heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_3)$alkoxy, $(C_1\text{-}C_3)$alkyl, and fluoro-substituted $(C_1\text{-}C_3)$alkyl;

a pharmaceutically acceptable salt thereof.

62. (Previously presented). The compound of Claim 59, 60, or 61 wherein R^{1a}, R^{1b}, R^{2a} and R^{2b} are each independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

63. (Previously presented). The compound of Claim 62 wherein R^{1a}, R^{1b}, R^{2a} and R^{2b} are each independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, fluoro-substituted $(C_1\text{-}C_4)$alkyl), and cyano; and

n and m are each independently 0 or 1;

a pharmaceutically acceptable salt thereof.

64. (Previously presented). The compound of Claim 58 wherein Y is $-C(R^{4d})(R^{4d'})-$, where R^{4d} is hydrogen, cyano, hydroxy, amino, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_4)$alkyl-NH-C(O)-, $(C_1\text{-}C_4)$alkyl)$_2$N-C(O)-, $(C_1\text{-}C_6)$alkylamino-, $((C_1\text{-}C_4)\text{alkyl})_2$amino-, $(C_3\text{-}C_6)$cycloalkylamino-, acylamino-, aryl$(C_1\text{-}C_4)$alkylamino-, heteroaryl$(C_1\text{-}C_4)$alkylamino-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a partially or fully

saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

$R^{4d'}$ is hydrogen, $H_2NC(O)$-, or a chemical moiety selected from the group consisting of (C_1-C_6)alkyl, acyl, (C_1-C_3)alkyl-O-C(O)-, (C_1-C_4)alkyl-NH-C(O)-, (C_1-C_4)alkyl)$_2$N-C(O)-, aryl, heteroaryl, a 3-6 membered partially or fully saturated heterocycle, and a partially or fully saturated carbocyclic ring, where said moiety is optionally substituted with one or more substituents,

or R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated carbocyclic ring, a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said carbocyclic ring, said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring and said lactam ring optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof.

65. (Previously presented). The compound of Claim 64 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen;

R^{4d} is amino, (C_1-C_6)alkylamino, di(C_1-C_4)alkylamino, (C_3-C_6)cycloalkylamino, acylamino, aryl(C_1-C_4)alkylamino-, heteroaryl(C_1-C_4)alkylamino-; and

$R^{4d'}$ is (C_1-C_6)alkyl, $H_2NC(O)$-, (C_1-C_4)alkyl-NH-C(O)-, or $((C_1-C_4)$alkyl)$_2$N-C(O)-, or aryl;

a pharmaceutically acceptable salt thereof.

66. (Previously presented). The compound of Claim 65 wherein

X is a bond or $-C(R^{4c})(R^{4c'})$-, where R^{4c} and $R^{4c'}$ are each hydrogen; and

Z is a bond or $-C(R^{4e})(R^{4e'})$-, where R^{4e} and $R^{4e'}$ are each hydrogen;

a pharmaceutically acceptable salt thereof.

67. (Previously presented). The compound of Claim 66 wherein R^{4d} is amino, (C_1-C_6)alkylamino, di(C_1-C_4)alkylamino, (C_3-C_6)cycloalkylamino; and

$R^{4d'}$ is $H_2NC(O)$-, (C_1-C_4)alkyl-NH-C(O)-, or $((C_1-C_4)$alkyl)$_2$N-C(O)-;

a pharmaceutically acceptable salt thereof.

68. (Previously presented). The compound of Claim 64, 65, 66 or 67 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

69. (Previously presented). The compound of Claim 68 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, fluoro-substituted $(C_1\text{-}C_4)$alkyl), and cyano; and

n and m are each independently selected from 0 or 1;

a pharmaceutically acceptable salt thereof.

70. (Previously presented). The compound of Claim 64 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen;

R^{4d} is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, acyloxy, acyl, $(C_1\text{-}C_3)$alkyl-O-C(O)-, $(C_1\text{-}C_6)$alkylamino-, and di$(C_1\text{-}C_4)$alkylamino-, where said moiety is optionally substituted with one or more substituents; and

$R^{4d'}$ is hydrogen, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl, aryl and heteroaryl, where said moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof.

71. (Previously presented). The compound of Claim 70 wherein

X is a bond or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each independently hydrogen or an optionally substituted $(C_1\text{-}C_6)$alkyl, or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond, a methylene bridge or an ethylene bridge; and

Z is a bond or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each independently hydrogen or an optionally substituted $(C_1\text{-}C_6)$alkyl, or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

72. (Previously presented). The compound of Claim 71 wherein

R^{4c} and $R^{4c'}$ are each hydrogen or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond;

R^{4d} is hydrogen, hydroxy, amino, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkoxy, acyl, $(C_1\text{-}C_6)$alkylamino-, and di$(C_1\text{-}C_4)$alkylamino-;

$R^{4d'}$ is hydrogen, or a chemical moiety selected from the group consisting of $(C_1\text{-}C_6)$alkyl and aryl, where said moiety is optionally substituted with one or more substituents; and

R^{4e} and $R^{4e'}$ are hydrogen or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond;

a pharmaceutically acceptable salt thereof.

73. (Previously presented). The compound of Claim 70, 71, or 72 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

74. (Previously presented). The compound of Claim 73 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, fluoro-substituted $(C_1\text{-}C_4)$alkyl), and cyano; and

n and m are each independently 0 or 1;

a pharmaceutically acceptable salt thereof.

75. (Previously presented). The compound of Claim 64 wherein

R^{4b}, $R^{4b'}$, R^{4f}, and $R^{4f'}$ are all hydrogen; and

R^{4d} and $R^{4d'}$ taken together form a 3-6 membered partially or fully saturated carbocyclic ring, a 3-6 membered partially or fully saturated heterocyclic ring, a 5-6 membered lactone ring, or a 4-6 membered lactam ring, where said carbocyclic ring, said heterocyclic ring, said lactone ring and said lactam ring are optionally substituted with one or more substituents and said lactone ring or said lactam ring optionally contains an additional heteroatom selected from oxygen, nitrogen or sulfur;

a pharmaceutically acceptable salt thereof.

76. (Previously presented). The compound of Claim 75 wherein

X is a bond, $-CH_2CH_2-$ or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each independently hydrogen or an optionally substituted $(C_1\text{-}C_6)$alkyl, or either R^{4c} or $R^{4c'}$ taken together with R^{4e} or $R^{4e'}$ forms a bond, a methylene bridge or an ethylene bridge; and

Z is a bond, $-CH_2CH_2-$ or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each independently hydrogen or an optionally substituted (C_1-C_6)alkyl, or either R^{4e} or $R^{4e'}$ taken together with R^{4c} or $R^{4c'}$ forms a bond, a methylene bridge or an ethylene bridge;

a pharmaceutically acceptable salt thereof.

77. (Previously presented). The compound of Claim 76 wherein R^{4d} and $R^{4d'}$ taken together form a 5-6 membered lactam ring, where said lactam ring is optionally substituted with one or more substituents and optionally contains an additional heteroatom selected from nitrogen or oxygen;

a pharmaceutically acceptable salt thereof.

78. (Previously presented). The compound of Claim 77 wherein

X is a bond or $-C(R^{4c})(R^{4c'})-$, where R^{4c} and $R^{4c'}$ are each hydrogen; and

Z is a bond or $-C(R^{4e})(R^{4e'})-$, where R^{4e} and $R^{4e'}$ are each hydrogen;

a pharmaceutically acceptable salt thereof.

79. (Previously presented). The compound of Claim 75, 76, 77 or 78 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, and cyano;

a pharmaceutically acceptable salt thereof.

80. (Previously presented). The compound of Claim 79 wherein R^{1a}, R^{1b}, R^{2a}, and R^{2b} are each independently selected from the group consisting of chloro, fluoro, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, fluoro-substituted (C_1-C_4)alkyl), and cyano;

n and m are each independently 0 or 1;

a pharmaceutically acceptable salt thereof.

81-96 (Cancelled).

97. (Previously presented). A pharmaceutical composition comprising (1) a compound of Claim 1, or a pharmaceutically acceptable salt thereof; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

98-100 (Cancelled).

101. (Previously presented). A method for treating obesity in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1

a pharmaceutically acceptable salt thereof.

102-107 (Cancelled).

108. (Previously presented). A method for treating obesity in an animal comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a pharmaceutical composition of Claim 97.

109-119 (Cancelled).

120. (Previously presented). A compound having the structure



121. (Previously presented). A compound which is 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide;

or a pharmaceutically acceptable salt thereof.